Agilent buys Biovectra

Agilent Technologies, a major player in analytical and clinical laboratory services, has agreed to acquire Canadian biotech and pharmaceutical CDMO Biovectra from HIG Capital in a $925 million deal that is expected to close before 2025. This covers all Biovectra’s employees and sites in Prince Edward Island and Nova Scotia.

“The acquisition expand Agilent’s end-to-end biopharma solutions with Biovectra’s biologics capabilities to accelerate drug development and manufacturing,” the two companies stated. Industry rumour had previously linked Biovectra with Thermo Fisher.

Founded in 1970, Biovectra had been owned by HIG Capital since 2019. It recently spent $240 million on capital investments to expand its operational footprint at both sites and has also just completed a biologics expansion of capabilities in mRNA, pDNA, lipid nanoparticles and sterile fill/finish work.